The Latest Breaking News from Zoetis

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

Despite Zoetis significantly trailing behind the Nasdaq Composite over the past three months, analysts seem extremely bullish on the stock’s prospects due to its robust product pipeline and global reach.

Zoetis stock crumbled Friday after a report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats.

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).

The Victorian government has purchased the former CSL site in Melbourne's inner north and on-sold part of the land to an animal vaccine giant.

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

Zoetis stock shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Some 47 Fortune 500 CEOs have spent time as management consultants but first took more junior roles.